Ligand Pharmaceuticals Incorporated Earnings Dividend

Ligand Pharmaceuticals Incorporated’s revenue jumped 39.37% since last year same period to $59.67Mn in the Q4 2025. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated has generated -48.32% fall in its revenue since last 3-months.

Ligand Pharmaceuticals Incorporated’s net profit jumped 244.06% since last year same period to $44.78Mn in the Q4 2025. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated has generated -61.81% fall in its net profits since last 3-months.

Ligand Pharmaceuticals Incorporated’s net profit margin jumped 203.36% since last year same period to 75.06% in the Q4 2025. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated has generated -26.1% fall in its net profit margins since last 3-months.

Ligand Pharmaceuticals Incorporated’s earning per share (EPS) estimates for the current quarter stand at 1.65 - a 10.74% jump from last quarter’s estimates.

Ligand Pharmaceuticals Incorporated’s earning per share (EPS) estimates for the current year stand at 1.65.

Ligand Pharmaceuticals Incorporated’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Ligand Pharmaceuticals Incorporated has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.